Raising high-density lipoprotein cholesterol "what does 2008 offer?"

HDL Forum spoke to Professor Philip Barter, Director of the Heart Research Institute, and Professor Kerry-Anne Rye, Head of the Lipid Research Group, Heart Research Institute, Sydney, Australia about new therapeutic developments for raising high-density lipoprotein (HDL) cholesterol, "good" cholesterol, in 2008
Read more...

New analysis from TNT study highlights importance of HDL cholesterol

A low level of HDL cholesterol remains predictive of major cardiovascular events even in statin-treated patients who achieved LDL cholesterol levels < 70 mg/dL (1.8 mmol/L), according to new data from the Treating to New Targets (TNT) study, published in the September 27, 2007 issue of the New England Journal of Medicine.
Read more...

What do the torcetrapib trials tells us?

The results of three trials investigating the effects of the CETP inhibitor, torcetrapib, on atherosclerosis progression were presented at the annual meeting of the American College of Cardiology held in New Orleans in March 2007.
Read more...

Top 10 HDL papers for 2006

The editors present the top 10 HDL papers for 2006 that have increased understanding of some of the fundamentally important events in which HDL participate, such as the inhibition of inflammation and enhanced cholesterol efflux.
Read more...

Functionally defective HDL in diabetic dyslipidaemia: new therapeutic horizons

Cardiovascular disease (CVD) is the most common cause of mortality, responsible for about one-third of all deaths globally, according to recent estimates from the World Health Organization.
Read more...

Why we need new therapeutic strategies for raising HDL-C

Epidemiological and observational studies have conclusively established low HDL-C as a strong, independent predictor of coronary heart disease (CHD). Conversely, subjects with high levels of HDL-C have a reduced CHD risk
Read more...

How can we manage diabetic dyslipidaemia to reduce cardiovascular risk?

Dyslipidemia is one of the main risk factors responsible for the increased cardiovascular risk associated with type 2 diabetes. We clearly need to consider treatment effective against all components of this dyslipidaemia, to reduce this risk.
Read more...

For further information, Professor Philip Barter, Heart Research Institute, Sydney, Australia gives a lecture on Diabetes and cardiovascular risk on Dave.md